Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Forecasted to Post FY2022 Earnings of ($0.62) Per Share

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) – Stock analysts at Zacks Investment Research decreased their FY2022 earnings estimates for shares of Brainstorm Cell Therapeutics in a research report issued to clients and investors on Tuesday, May 24th. Zacks Investment Research analyst D. Bautz now anticipates that the biotechnology company will earn ($0.62) per share for the year, down from their previous estimate of ($0.60).

Separately, StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics in a research report on Sunday. They set a “hold” rating on the stock.

NASDAQ BCLI opened at $2.90 on Thursday. The firm has a market capitalization of $105.81 million, a price-to-earnings ratio of -4.53 and a beta of 0.05. The firm’s 50 day simple moving average is $3.14 and its 200 day simple moving average is $3.27. Brainstorm Cell Therapeutics has a 1 year low of $2.65 and a 1 year high of $4.46.

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) last posted its quarterly earnings results on Monday, May 16th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). During the same period last year, the business posted ($0.19) EPS.

A number of large investors have recently modified their holdings of BCLI. GSA Capital Partners LLP lifted its stake in Brainstorm Cell Therapeutics by 185.6% in the 3rd quarter. GSA Capital Partners LLP now owns 172,056 shares of the biotechnology company’s stock valued at $568,000 after purchasing an additional 111,818 shares during the last quarter. Weaver Consulting Group raised its stake in shares of Brainstorm Cell Therapeutics by 201.9% during the fourth quarter. Weaver Consulting Group now owns 155,500 shares of the biotechnology company’s stock valued at $622,000 after acquiring an additional 104,000 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Brainstorm Cell Therapeutics by 27.5% during the first quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock valued at $827,000 after acquiring an additional 53,036 shares during the last quarter. Abner Herrman & Brock LLC raised its stake in shares of Brainstorm Cell Therapeutics by 13.7% during the first quarter. Abner Herrman & Brock LLC now owns 265,000 shares of the biotechnology company’s stock valued at $890,000 after acquiring an additional 32,000 shares during the last quarter. Finally, Morgan Stanley raised its stake in shares of Brainstorm Cell Therapeutics by 42.3% during the second quarter. Morgan Stanley now owns 53,685 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 15,964 shares during the last quarter. 12.28% of the stock is owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics (Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Further Reading